Market Overview

Swedish Orphan Biovitrum AB Confirms Receipt of Preliminary and Conditional Non-binding Proposal for Acquisition of All Shares Issued by Company

Sobi and Biogen's Elocta Approved by EC for Treatment of Haemophilia A
Benzinga's M&A Chatter for Monday April 27, 2015
Related PFE
Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold (Seeking Alpha)

The Board of Swedish Orphan Biovitrum AB (OTC: SWTUY) notes the recent speculation in the press and elsewhere regarding a potential acquisition of the company.
The Board confirms that it has received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company.
There can be no certainty that an offer will be made, nor as to the terms of any such offer. A further announcement will be made when appropriate.

Posted-In: News M&A Press Releases


Related Articles (BIIB + PFE)

View Comments and Join the Discussion!